JPRN-UMIN000028965已完成1 期
Transhepatic arterial administration of G-CSF mobilized autologous peripheral blood CD34 positive cells in patients with hepatitis C virus-related liver cirrhosis - Transhepatic arterial administration of G-CSF mobilized autologous peripheral blood CD34 positive cells in patients with hepatitis C virus-related decompensated liver cirrhosis
Kurume University School of Medicine0 个研究点目标入组 24 人开始时间: 2017年9月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with HCV-related liver cirrhosis or cryptogenic liver cirrhosis 2) Patients who are positive for HBs-Ag, HIV-Ab, HTLV1-Ab, serological test for syphilis and HBc-Ab (CLIA method >10.00 S/CO) 3) Patients with alcoholic drinkers, Patients with a Child-Pugh Score less than or equal to 6 points in whom further improvement with abstinence for more than 6 months. 4) Patients complicated of malignant tumor or patients with a history of malignant tumor within 5 years (However, for patients with a history of intraepithelial carcinoma [e.g., colon mucosal cancer] and hepatocellular carcinoma, which are negative for AFP and PIVKA-II, is not excluded) 5) Total bilirubin> 5.0 mg/dL 6) Prothrombin time less than 30% 7) Serum creatinine> 2.0 mg/dL 8) Hemoglobin less than 8 g/dL 9) Platelet less than 20,000 / uL 10) Patients who have splenomegaly with longitudinal spleen diameter more than 15 cm by abdominal CT 11) Patients who have gastrointestinal bleeding or patients who may cause bleeding in the gastrointestinal tract 12) Patients with portal vein thrombosis 13) Patients currently suffering from or having a history of interstitial pneumonia 14) Patients with hematological disease (leukemia, myeloproliferative disease, myelodysplastic syndrome or sickle cell anemia) 15) Patients with autoimmune disease 16) Patients with less than 3 months since last episode of unstable angina, myocardial/cerebral infarction, Patients with less than 3 months since coronary artery/carotid artery/intracranial artery stenting 17) Patients with proliferative diabetic retinopathy 18) Patients with a history of severe allergic reactions or side effects to G-CSF, apheresis, or a contrast agents 19) Pregnant women, lactating women, patients who may be pregnant, female patients planning pregnancy during the study period 20) Any other reason that the Clinical Supervision or Clinical Researchers may have for considering a case unsuitable for the study
研究者
相似试验
已完成
1 期
Transhepatic arterial administration of G-CSF mobilized autologous peripheral blood CD34 positive cells in patients with hepatitis C virus-related decompensated liver cirrhosisDecompensated liver cirrhosis (Hepatitis C virus-related)JPRN-jRCTb070190052akamura Toru14
已完成
不适用
Hepatic arterial infusion of autologous gamma/delta T cell for advanced hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000011184The University of Tokyo Hospital15
进行中（未招募）
3 期
A Phase III randomized, double-blinded, placebo-controlled trial to investigate the impact of intra-coronary transfusion of G-CSF mobilized autologous circulating hematopoietic stem/progenitor cells (CPC) therapy in patients with diffuse coronary artery disease who are not candidates for coronary artery interventioDiffuse Coronary Artery Disease (CAD) and non candidates for coronary artery interventionCirculatory SystemISRCTN14054375Chang Gung Memorial Hospital, Chang Gung Medical Foundation96
已完成
1 期
Phase I/II trial of hepatic arterial infusion of FMP therapy for advanced hepatocellular carcinomaadvanced hepatocellular carcinomaJPRN-UMIN000000487Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital45
进行中（未招募）
不适用
Intra-Arterial hepatic administration of SIR-Spheres for the advanced HEPATOCARCINOMA. CLINICAL TRIAL OF PHASE II - NDEUCTR2005-005183-82-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI20